Cargando…
Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma
Rationale: The onset of cytokine release syndrome (CRS) and in vivo persistence of anti-CD19 chimeric antigen receptor T (CAR-T) cells after infusion correlate with clinical responsiveness. However, there are no known baseline biomarkers that can predict the prognosis of patients with B-lineage non-...
Autores principales: | Jia, Qingzhu, Qin, Diyuan, He, Feng, Xie, Qichao, Ying, Zhitao, Zhang, Yajing, Song, Yuqin, Cheng, Jia-Nan, Zuo, Xuejiao, Xu, Luxiang, Fang, Hongliang, Hu, Chunyan, Peng, Lina, Jin, Tao, Shi, Zixiao, Alexander, Peter B., Wang, Yongsheng, Liu, Yarong, Han, Weidong, Zhu, Jun, Wang, Pin, Li, Qi-Jing, Zhu, Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7978305/ https://www.ncbi.nlm.nih.gov/pubmed/33754022 http://dx.doi.org/10.7150/thno.54546 |
Ejemplares similares
-
A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma
por: Ying, Zhitao, et al.
Publicado: (2022) -
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
por: Wei, Jianshu, et al.
Publicado: (2020) -
Exploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies
por: Zhang, Yugu, et al.
Publicado: (2023) -
Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s Lymphoma
por: Ying, Zhitao, et al.
Publicado: (2019) -
Challenges and optimal strategies of CAR T therapy for hematological malignancies
por: Zhang, Yajing, et al.
Publicado: (2023)